Erick Wayne DeVinney, Vice President of Peripheral Nerve Science, has demonstrated a consistent pattern of selling activity in Axogen, Inc. (AXGN) shares, with no recorded purchases across 29 transactions totaling over $2.04 million in proceeds since March 2024. His most recent disposals occurred on March 16, 2026, when he sold $171,457 worth of shares and exercised derivative securities for $94,250 in value. This follows earlier sales on March 1, 2026 ($345,609) and February 26, 2026 ($341,393), reinforcing a multi-year trend of reducing his AXGN position. The largest single transaction came on December 9, 2025, when he disposed of $609,086 in stock.
DeVinney's trading history shows a clear preference for liquidating holdings through both open market sales (coded "S") and derivative transactions (coded "F"), with all activity concentrated in Axogen. The absence of any buy transactions suggests either portfolio rebalancing or systematic divestment of his position in the medical technology firm. Notably, his sales have accelerated in frequency and size since late 2025, with seven disposals in the most recent reporting period accounting for approximately $1.36 million of the total proceeds. The transactions occur alongside routine equity award adjustments (coded "A" and "M") that show no monetary value changing hands.
AI-assisted summary